|

Imlunestrant Clinical Trials

3 actively recruiting trials across 3 locations

▲ +1 trial since July 2026

Also known as: Inluriyo, LY3484356

Pipeline

Phase 1: 1Phase 2: 1Phase 1/2: 1

Top Sponsors

  • Eli Lilly and Company3

Indications

Birmingham, Alabama1 trial

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

University of Alabama at Birmingham

Phase 2

Scottsdale, Arizona1 trial

A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors

Mayo Clinic of Scottsdale

Phase 1

Los Angeles, California1 trial

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Ellison Clinic at Saint John's

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.